Shots:

• The company plan to initiate a pivotal P-IIIa program to assess the efficacy and safety of oral semaglutide (50mg) vs PBO in ~1000 people with obesity or overweight with comorbidities for 68wks.
• The initiation follows the completion of the STEP P-IIIa clinical program with semaglutide (2.4mg- qw- SC). The study is expected to initiate the study in H2’21
• Oral semaglutide is a convenient and effective treatment option for people with obesity and HCPs enabling broader use of anti-obesity medication

  Ref: Globe Newswire | Image: Mehr News Agency